Clinical trials: SARS-COV2 Virus
COVID-19, SARS-CoV-2 Infection
Safety and Immunogenicity of NVX-CoV2705
This study is a Phase 3 trial designed to check the safety and immune response to a new Omicron JN.1 COVID-19 vaccine. Study researchers will give a single dose of this vaccine, called NVX-CoV2705, to approximately 120…
- Trial name
- COVID-19 (NCT07079670)
- Testing
- NVX-CoV2705
- Where
- 10 sites in United States
- Volunteers
- 676 people, healthy volunteers welcome
- Sponsor
- Sanofi
Infection, Respiratory Tract
Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic
The aim of this study is to investigate whether vaccination of healthcare professionals with VPM1002 could reduce the number of days absent from work due to respiratory disease (with or without documented SARS-CoV-2 infection).
- Trial name
- NCT04387409
- Testing
- VPM1002
- Where
- 3 sites in Germany
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Serum Life Science Europe GmbH
COVID-19 Drug Treatment
Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19
In the context of COVID-19 pandemic, a report on ivermectin suppression of SARS-CoV-2 viral replication in cell cultures has been published, and the use of this medication seems to be potentially useful for the therapy.
- Trial name
- NCT04381884
- Testing
- IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.
- Where
- 3 sites in Argentina
- Volunteers
- 45 people
- Sponsor
- Laboratorio Elea Phoenix S.A.
COVID-19, SARS-CoV2
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
The purpose of this clinical trial is to determine the efficacy of Previfenon® (EGCG) to prevent COVID-19, enhance systemic immunity, and decrease the frequency and intensity of selected symptoms when used as pre-exposure…
- Trial name
- HERD (NCT04446065)
- Testing
- Previfenon®
- Volunteers
- healthy volunteers welcome
- Sponsor
- MELISA Institute Genomics & Proteomics Research SpA
Influenza
Detection of Influenza or SARS-CoV-2 Infection by IMS of Nasal Air Sampling
Multicapillary Ion mobility spectrometry of nasal air aspirates shall be investigated as screening tool for the detection of Influenza and SARS-CoV-2- infection.
- Trial name
- NCT04282135
- Testing
- MCC IMS
- Where
- Germany
- Volunteers
- 76 people
- Sponsor
- Klinikum Bayreuth GmbH
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children.
- Conditions
- SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
- Trial name
- NCT05543616
- Testing
- Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose
- Where
- 96 sites in United States, Brazil and 3 more
- Volunteers
- 4,338 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
SARS-CoV-2 Infection
A Study to Learn About PAXLOVID (a Commercial Medicine) In People With COVID-19
The purpose of this post marketing observational study is to learn about the safety and effects of the commercial medicine (called PAXLOVID) for the treatment of COVID-19.
- Trial name
- NCT05263908
- Testing
- nirmatrelvir / ritonavir
- Where
- Japan
- Volunteers
- 3,346 people
- Sponsor
- Pfizer
COVID-19, SARS CoV 2 Infection
To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M
ProLectin M is an orally administered polysaccharide. Polysaccharides competitively bind to the N-terminal tail of human galectin-3 through a proline isomerization [10].
- Trial name
- NCT05733780
- Testing
- Prolectin-M
- Volunteers
- 40 people
- Sponsor
- Bioxytran Inc.
Covid19
Dräger COVID-19 Antigen Test Clinical Performance Study
The study is designed to demonstrate suitability of the Dräger Antigen Test for SARS-CoV-2 detection in clinical nasal specimens.
- Trial name
- NCT04698993
- Testing
- Dräger Antigen Test SARS-CoV-2
- Where
- Germany
- Volunteers
- 388 people
- Sponsor
- Drägerwerk AG & Co. KGaA
COVID-19
Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness
This is a Phase 1 and phase 2, adaptive, placebo-controlled, double-blind, randomized single-dose study in participants with Severe COVID-19 illness.
- Trial name
- NCT05303376
- Testing
- IBIO123
- Where
- 5 sites in South Africa, Ukraine
- Volunteers
- 123 people
- Sponsor
- Immune Biosolutions Inc
Covid19, SARS-CoV Infection
A Virtual Prospective Study Exploring Activity Trackers and COVID-19 Infections
Prospective, observational, exploratory study exploring the relationship between passively-collected data from wearable activity devices and SARS-CoV-2 infection
- Trial name
- NCT04623138
- Where
- United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- Evidation Health
COVID-19
A Study to Evaluate Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant (COVID-19) mRNA Vaccines
A Phase 1 study to evaluate safety, tolerability, and immunogenicity of SARS-CoV-2 variant mRNA vaccines which are used to prevent COVID-19 caused by SARS-CoV-2 infection.
- Trial name
- NCT05434585
- Testing
- ABO1009-DP, ABO-CoV.617.2
- Where
- 2 sites in Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Covid19
Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19
This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Novaferon, in hospitalized adult patients diagnosed with COVID-19.
- Trial name
- NOVATION-1 (NCT04669015)
- Testing
- Novaferon
- Where
- 88 sites in Argentina, Brazil and 10 more
- Volunteers
- 914 people
- Sponsor
- Genova Inc.
SARS-CoV-2
Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals
The objective of the study is to demonstrate safety and immunogenicity of COVID-19 preventive DNA vaccine in elderly individuals.
- Trial name
- NCT04915989
- Testing
- GX-19N
- Where
- 2 sites in South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Genexine, Inc.
COVID-19
Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine
This study is a retrospective case control analysis on the real-world effectiveness of the Pfizer-BioNTech BNT162b2 vaccine (2024-2025 formulation) against symptomatic SARS-CoV-2 infection among CVS MinuteClinic patients testing…
- Trial name
- C4591068 (NCT06703190)
- Testing
- Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated, Not vaccinated with 2024-2025 formulated COVID-19 vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
SARS-CoV-2, COVID-19 Vaccine
Safety and Immunogenicity of Recombinant COVID-19 Trivalent Protein Vaccine （CHO Cell）LYB002V14 in Booster Vaccination
This is a randomized, blinded, and dose escalation phase I trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT06167915
- Testing
- 30μg dose of LYB002V14, 60μg dose of LYB002V14
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Guangzhou Patronus Biotech Co., Ltd.
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Covid19
Evaluating the Impact of EnteraGam In People With COVID-19
Background: Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), emerged as a potentially life-threatening disease in Wuhan, China, at the end of 2019.
- Trial name
- PICNIC (NCT04682041)
- Testing
- Bovine Plasma-Derived Immunoglobulin Concentrate, Standard of care
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Entera Health, Inc
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U
COVID-19
Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.
CALAVI US will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together with Best Supportive Care in the treatment of COVID-19.
- Trial name
- CALAVI US (NCT04380688)
- Testing
- Acalabrutinib
- Where
- 31 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca